All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

MPN Types

Why does adding navitoclax to ruxolitinib induce responses in patients with R/R MF?

By Amalia Zachariadis, Becky Lowe, Paola Frisone

Featured

Naveen Pemmaraju

Jan 5, 2021

Video series

ASH 2020 highlights for myelofibrosis

1

6:05

What do the preliminary results of the MANIFEST trial say about CPI-0610...

Alessandro M. Vannucchi

2

4:03

SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment...

Ruben A. Mesa

3

3:56

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with...

Srdan Verstovsek

4:10

Why does adding navitoclax to ruxolitinib induce responses in patients...

Naveen Pemmaraju

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, Why does adding navitoclax to ruxolitinib induce responses in patients with relapsed/refractory myelofibrosis?

Pemmaraju reports the results of a study evaluating the addition of navitoclax to ruxolitinib in 34 patients with myelofibrosis who lost response to ruxolitinib.